Which has stronger earnings and valuation, QNCX or IMMP?

Prima BioMed has higher revenue and earnings than Quince Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quince Therapeutics N/A N/A -$83.98M -$10.62 N/A Prima BioMed $4.08M 15.21 -$39.78M N/A N/A

Is QNCX or IMMP more profitable?

Prima BioMed's return on equity of 0.00% beat Quince Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A -372.88% -67.99% Prima BioMed N/A N/A N/A

Does the media refer more to QNCX or IMMP?

In the previous week, Prima BioMed had 18 more articles in the media than Quince Therapeutics. MarketBeat recorded 20 mentions for Prima BioMed and 2 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 1.89 beat Prima BioMed's score of 0.12 indicating that Quince Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Prima BioMed 0 Very Positive mention(s) 1 Positive mention(s) 18 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LFVN or QNCX?

In the previous week, Lifevantage had 2 more articles in the media than Quince Therapeutics. MarketBeat recorded 4 mentions for Lifevantage and 2 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 1.89 beat Lifevantage's score of 0.62 indicating that Quince Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifevantage 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quince Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor QNCX or TCRX?

In the previous week, TScan Therapeutics had 1 more articles in the media than Quince Therapeutics. MarketBeat recorded 3 mentions for TScan Therapeutics and 2 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 1.89 beat TScan Therapeutics' score of 0.94 indicating that Quince Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive TScan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MNOV or QNCX?

In the previous week, MediciNova had 1 more articles in the media than Quince Therapeutics. MarketBeat recorded 3 mentions for MediciNova and 2 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 1.89 beat MediciNova's score of 0.97 indicating that Quince Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediciNova 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quince Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger earnings & valuation, QNCX or PMVP?

PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quince Therapeutics N/A N/A -$83.98M -$10.62 N/A PMV Pharmaceuticals N/A N/A -$77.74M -$1.49 N/A

Is QNCX or PMVP more profitable?

PMV Pharmaceuticals' return on equity of -68.98% beat Quince Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A -372.88% -67.99% PMV Pharmaceuticals N/A -68.98% -62.70%

Quince Therapeutics (QNCX) Competitors

$1.06 -0.05 (-4.05%)

As of 02:28 PM Eastern

Compare

QNCX vs. IMMP, LFVN, TCRX, MNOV, and PMVP

Should you buy Quince Therapeutics stock or one of its competitors? MarketBeat compares Quince Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Quince Therapeutics include Prima BioMed (IMMP), Lifevantage (LFVN), TScan Therapeutics (TCRX), MediciNova (MNOV), and PMV Pharmaceuticals (PMVP). These companies are all part of the "pharmaceutical products" industry.

How does Quince Therapeutics compare to Prima BioMed?

Quince Therapeutics (NASDAQ:QNCX) and Prima BioMed (NASDAQ:IMMP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

Prima BioMed has higher revenue and earnings than Quince Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$10.62	N/A
Prima BioMed	$4.08M	15.21	-$39.78M	N/A	N/A

In the previous week, Prima BioMed had 18 more articles in the media than Quince Therapeutics. MarketBeat recorded 20 mentions for Prima BioMed and 2 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 1.89 beat Prima BioMed's score of 0.12 indicating that Quince Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quince Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Prima BioMed	0 Very Positive mention(s)	1 Positive mention(s)	18 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prima BioMed's return on equity of 0.00% beat Quince Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	-372.88%	-67.99%
Prima BioMed	N/A	N/A	N/A

Quince Therapeutics has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.24, meaning that its stock price is 124% more volatile than the broader market.

Quince Therapeutics currently has a consensus target price of $65.00, indicating a potential upside of 6,003.29%. Prima BioMed has a consensus target price of $5.50, indicating a potential upside of 1,206.41%. Given Quince Therapeutics' higher probable upside, research analysts clearly believe Quince Therapeutics is more favorable than Prima BioMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Prima BioMed	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 2.3% of Prima BioMed shares are owned by institutional investors. 7.1% of Quince Therapeutics shares are owned by insiders. Comparatively, 3.1% of Prima BioMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Prima BioMed beats Quince Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Quince Therapeutics compare to Lifevantage?

Lifevantage (NASDAQ:LFVN) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

Lifevantage has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

35.3% of Lifevantage shares are owned by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are owned by institutional investors. 22.0% of Lifevantage shares are owned by insiders. Comparatively, 7.1% of Quince Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Lifevantage has higher revenue and earnings than Quince Therapeutics. Quince Therapeutics is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifevantage	$228.53M	0.48	$9.81M	$0.45	19.38
Quince Therapeutics	N/A	N/A	-$83.98M	-$10.62	N/A

Lifevantage has a net margin of 2.94% compared to Quince Therapeutics' net margin of 0.00%. Lifevantage's return on equity of 23.89% beat Quince Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifevantage	2.94%	23.89%	12.47%
Quince Therapeutics	N/A	-372.88%	-67.99%

Lifevantage currently has a consensus target price of $5.00, indicating a potential downside of 42.67%. Quince Therapeutics has a consensus target price of $65.00, indicating a potential upside of 6,003.29%. Given Quince Therapeutics' higher probable upside, analysts clearly believe Quince Therapeutics is more favorable than Lifevantage.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

In the previous week, Lifevantage had 2 more articles in the media than Quince Therapeutics. MarketBeat recorded 4 mentions for Lifevantage and 2 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 1.89 beat Lifevantage's score of 0.62 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifevantage	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quince Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Lifevantage beats Quince Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Quince Therapeutics compare to TScan Therapeutics?

Quince Therapeutics (NASDAQ:QNCX) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Quince Therapeutics has higher earnings, but lower revenue than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$10.62	N/A
TScan Therapeutics	$10.32M	6.22	-$129.77M	-$0.96	N/A

30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 7.1% of Quince Therapeutics shares are owned by company insiders. Comparatively, 6.3% of TScan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Quince Therapeutics has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

Quince Therapeutics has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. TScan Therapeutics' return on equity of -91.94% beat Quince Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	-372.88%	-67.99%
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%

In the previous week, TScan Therapeutics had 1 more articles in the media than Quince Therapeutics. MarketBeat recorded 3 mentions for TScan Therapeutics and 2 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 1.89 beat TScan Therapeutics' score of 0.94 indicating that Quince Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quince Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
TScan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quince Therapeutics currently has a consensus price target of $65.00, suggesting a potential upside of 6,003.29%. TScan Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 510.38%. Given Quince Therapeutics' higher possible upside, research analysts clearly believe Quince Therapeutics is more favorable than TScan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

TScan Therapeutics beats Quince Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Quince Therapeutics compare to MediciNova?

MediciNova (NASDAQ:MNOV) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

In the previous week, MediciNova had 1 more articles in the media than Quince Therapeutics. MarketBeat recorded 3 mentions for MediciNova and 2 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 1.89 beat MediciNova's score of 0.97 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediciNova	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quince Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Quince Therapeutics has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat Quince Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,962.98%	-27.28%	-25.24%
Quince Therapeutics	N/A	-372.88%	-67.99%

9.9% of MediciNova shares are owned by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are owned by institutional investors. 14.0% of MediciNova shares are owned by company insiders. Comparatively, 7.1% of Quince Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

MediciNova has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

MediciNova presently has a consensus price target of $7.50, suggesting a potential upside of 455.56%. Quince Therapeutics has a consensus price target of $65.00, suggesting a potential upside of 6,003.29%. Given Quince Therapeutics' higher possible upside, analysts plainly believe Quince Therapeutics is more favorable than MediciNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

MediciNova has higher revenue and earnings than Quince Therapeutics. MediciNova is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410K	162.07	-$12M	-$0.23	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$10.62	N/A

Summary

MediciNova beats Quince Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Quince Therapeutics compare to PMV Pharmaceuticals?

Quince Therapeutics (NASDAQ:QNCX) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

Quince Therapeutics currently has a consensus price target of $65.00, indicating a potential upside of 6,003.29%. PMV Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 301.61%. Given Quince Therapeutics' higher possible upside, analysts plainly believe Quince Therapeutics is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Quince Therapeutics had 1 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 2 mentions for Quince Therapeutics and 1 mentions for PMV Pharmaceuticals. Quince Therapeutics' average media sentiment score of 1.89 equaled PMV Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Quince Therapeutics	Very Positive
PMV Pharmaceuticals	Very Positive

30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are held by institutional investors. 7.1% of Quince Therapeutics shares are held by company insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

PMV Pharmaceuticals' return on equity of -68.98% beat Quince Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	-372.88%	-67.99%
PMV Pharmaceuticals	N/A	-68.98%	-62.70%

Quince Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$10.62	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A

Summary

PMV Pharmaceuticals beats Quince Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Quince Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QNCX vs. The Competition

Export

Metric	Quince Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$18.75M	$3.37B	$6.39B	$12.59B
Dividend Yield	N/A	2.29%	2.69%	5.30%
P/E Ratio	-0.10	18.01	21.16	26.60
Price / Sales	N/A	183.22	512.63	95.38
Price / Cash	N/A	54.19	27.44	37.60
Price / Book	-0.17	6.52	9.81	6.77
Net Income	-$83.98M	$24.15M	$3.56B	$337.23M
7 Day Performance	-11.25%	-1.50%	0.31%	2.65%
1 Month Performance	-19.92%	0.95%	4.68%	6.63%
1 Year Performance	-89.95%	51.23%	31.03%	37.91%

Quince Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QNCX Quince Therapeutics	2.1585 of 5 stars	$1.07 -4.1%	$65.00 +6,003.3%	-89.2%	$18.75M	N/A	N/A	60	News Coverage Positive News Gap Up
IMMP Prima BioMed	2.6932 of 5 stars	$0.49 flat	$5.50 +1,031.9%	-79.2%	$71.61M	$6.69M	N/A	2,021	Trending News Gap Up
LFVN Lifevantage	3.0191 of 5 stars	$5.61 flat	$5.00 -10.9%	-26.8%	$70.78M	$228.53M	12.47	260	Gap Down
TCRX TScan Therapeutics	3.4437 of 5 stars	$1.06 flat	$6.00 +466.0%	-29.6%	$69.27M	$10.32M	N/A	100	Gap Up
MNOV MediciNova	3.6401 of 5 stars	$1.40 flat	$7.50 +435.7%	-2.8%	$68.91M	$410K	N/A	10	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QNCX) was last updated on 6/2/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quince Therapeutics (QNCX) Competitors

QNCX vs. IMMP, LFVN, TCRX, MNOV, and PMVP

How does Quince Therapeutics compare to Prima BioMed?

Summary

How does Quince Therapeutics compare to Lifevantage?

Summary

How does Quince Therapeutics compare to TScan Therapeutics?

Summary

How does Quince Therapeutics compare to MediciNova?

Summary

How does Quince Therapeutics compare to PMV Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX vs. The Competition

Quince Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quince Therapeutics (QNCX) Competitors

QNCX vs. IMMP, LFVN, TCRX, MNOV, and PMVP

How does Quince Therapeutics compare to Prima BioMed?

Which has stronger earnings and valuation, QNCX or IMMP?

Does the media refer more to QNCX or IMMP?

Is QNCX or IMMP more profitable?

Which has more risk & volatility, QNCX or IMMP?

Do analysts recommend QNCX or IMMP?

Do insiders and institutionals believe in QNCX or IMMP?

Summary

How does Quince Therapeutics compare to Lifevantage?

Which has more risk and volatility, LFVN or QNCX?

Do insiders and institutionals have more ownership in LFVN or QNCX?

Which has preferable valuation and earnings, LFVN or QNCX?

Is LFVN or QNCX more profitable?

Do analysts rate LFVN or QNCX?

Does the media prefer LFVN or QNCX?

Summary

How does Quince Therapeutics compare to TScan Therapeutics?

Which has higher earnings and valuation, QNCX or TCRX?

Do institutionals and insiders hold more shares of QNCX or TCRX?

Which has more risk and volatility, QNCX or TCRX?

Is QNCX or TCRX more profitable?

Does the media favor QNCX or TCRX?

Do analysts rate QNCX or TCRX?

Summary

How does Quince Therapeutics compare to MediciNova?

Does the media refer more to MNOV or QNCX?

Is MNOV or QNCX more profitable?

Do institutionals and insiders hold more shares of MNOV or QNCX?

Which has more volatility & risk, MNOV or QNCX?

Do analysts rate MNOV or QNCX?

Which has better earnings & valuation, MNOV or QNCX?

Summary

How does Quince Therapeutics compare to PMV Pharmaceuticals?

Do analysts prefer QNCX or PMVP?

Does the media prefer QNCX or PMVP?

Do insiders & institutionals have more ownership in QNCX or PMVP?

Is QNCX or PMVP more profitable?

Which has more risk and volatility, QNCX or PMVP?

Which has stronger earnings & valuation, QNCX or PMVP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX vs. The Competition

Quince Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools